NewsFeeder
Headline News
- Reaction score
- 4
Alnylam rare drug gets FDA approval, to cost $345,000 on average
Alnylam Pharmaceuticals Inc.'s (ALNY) rare disease drug Onpattro has been approved by the Food and Drug Administration, marking the first approval of a therapy that employs the RNA interference (RNAi) gene-silencing technique. Onpattro, also called patisiran, is also the first FDA-approved drug for the rare and progressive disease hereditary ATTR amyloidosis with polyneuropathy, or malfunction of bodily nerves. It was shown in clinical trials to improve polyneuropathy and other symptoms.
https://finance.yahoo.com/m/d7495ea...2c2/alnylam-rare-drug-gets-fda.html?.tsrc=rss
Alnylam Pharmaceuticals Inc.'s (ALNY) rare disease drug Onpattro has been approved by the Food and Drug Administration, marking the first approval of a therapy that employs the RNA interference (RNAi) gene-silencing technique. Onpattro, also called patisiran, is also the first FDA-approved drug for the rare and progressive disease hereditary ATTR amyloidosis with polyneuropathy, or malfunction of bodily nerves. It was shown in clinical trials to improve polyneuropathy and other symptoms.
https://finance.yahoo.com/m/d7495ea...2c2/alnylam-rare-drug-gets-fda.html?.tsrc=rss
